Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD 17.66
-0.43 (-2.36%)
At close: Sep 17, 2025
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $611.09M USD in the quarter ending June 30, 2025, with 68.38% growth. This brings the company's revenue in the last twelve months to $2.48B, up 64.89% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.48B
Revenue Growth
+64.89%
P/S Ratio
0.67
Revenue / Employee
$1.81M
Employees
1,372
Market Cap
1.22B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Sarepta Therapeutics News
- 19 days ago - SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action - GlobeNewsWire
- 21 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 23 days ago - Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT - GlobeNewsWire
- 23 days ago - SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline - GlobeNewsWire
- 23 days ago - FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Business Wire
- 23 days ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - GlobeNewsWire
- 24 days ago - Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law Firm - PRNewsWire
- 24 days ago - SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - PRNewsWire